Latest & greatest articles for cancer

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on cancer or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for cancer

1. Pancreatic Cancer: Screening

Pancreatic Cancer: Screening Final Recommendation Statement: Pancreatic Cancer: Screening - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement Pancreatic Cancer: Screening Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency (...) for Healthcare Research and Quality or the U.S. Department of Health and Human Services. Recommendation Summary Population Recommendation Grade Adults The USPSTF recommends against screening for pancreatic cancer in asymptomatic adults. To read the recommendation statement in JAMA , select . To read the evidence summary in JAMA , select . Table of Contents Preface The US Preventive Services Task Force (USPSTF) makes recommendations about the effectiveness of specific preventive care services for patients

2019 U.S. Preventive Services Task Force

2. Rucaparib (Rubraca) - as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer

Rucaparib (Rubraca) - as monotherapy treatment of adult patients with platinum sensitive, relapsed or progressive, BRCA mutated (germline and/or somatic), high-grade epithelial ovarian, fallopian tube, or primary peritoneal cancer Published 12 August 2019 www.scottishmedicines.org.uk Statement of advice SMC2221 rucaparib 200mg, 250mg and 300mg film-coated tablets (Rubraca®) Clovis Oncology UK Ltd 5 July 2019 Advice context: No part of this advice may be used without the whole of the advice (...) peritoneal cancer, who have been treated with two or more prior lines of platinum based chemotherapy, and who are unable to tolerate further platinum based chemotherapy. The holder of the marketing authorisation has not made a submission to SMC regarding this product in this indication. As a result we cannot recommend its use within NHSScotland.

2019 Scottish Medicines Consortium

3. BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing

BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing Final Recommendation Statement: BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic Testing - US Preventive Services Task Force Search USPSTF Website Text size: Assembly version: 1.0.0.308 Last Build: 5/9/2019 1:01:08 PM You are here: Final Recommendation Statement : Final Recommendation Statement Final Recommendation Statement BRCA-Related Cancer: Risk Assessment, Genetic Counseling, and Genetic (...) Testing Recommendations made by the USPSTF are independent of the U.S. government. They should not be construed as an official position of the Agency for Healthcare Research and Quality or the U.S. Department of Health and Human Services. Recommendation Summary Population Recommendation Grade Women with a personal or family history of breast, ovarian, tubal, or peritoneal cancer or an ancestry associated with BRCA1/2 gene mutation The USPSTF recommends that primary care clinicians assess women

2019 U.S. Preventive Services Task Force

4. Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22)

Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III Colon Cancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22) Perioperative chemotherapy has proven valuable in several tumors, but not in colon cancer (CC).The aim of this study was to evaluate the efficacy and safety of perioperative chemotherapy in patients with locally advanced nonmetastatic CC.This is a French multicenter randomized phase II trial in patients

2019 EvidenceUpdates

5. Hereditary Gastrointestinal Cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up

Hereditary Gastrointestinal Cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up Hereditary gastrointestinal cancers: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up † N. Stjepanovic 1 , L. Moreira 2 , F. Carneiro 3 , F. Balaguer 2 , A. Cervantes 4 , J.Balmaña 1 & E. Martinelli 5 , on behalf of the ESMO Guidelines Committee* 1 Medical Oncology Department, University Hospital Vall d’Hebron, Barcelona, Spain; 2 Gastroenterology Department (...) Institute INCLIVA, University of Valencia, Valencia, Spain; 5 Faculty of Medicine, Università della Campania L Vanvitelli, Naples, Italy. *Correspondence to: ESMO Guidelines Committee, ESMO Head Office, Via Ginevra 4, 6900 Lugano, Switzerland. E-mail: clinicalguidelines@esmo.org † Approved by the ESMO Guidelines Committee: May 2019. Running header: ESMO Clinical Practice Guidelines Hereditary gastrointestinal cancers Word count: 5758 (excluding key message, references, tables & figures) Key words

2019 European Society for Medical Oncology

6. ADDENDUM: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment

ADDENDUM: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment Addendum: A practice guideline from the American College of Medical Genetics and Genomics and the National Society of Genetic Counselors: referral indications for cancer predisposition assessment Michael T. Bashford, MD 1 , Wendy Kohlman, MS 2 , Jessica Everett, MS 3 , Ashley Parrott, MS 4 and Toni I (...) with the following comment: The committees feel that this document remains a useful guide in assessing indications for cancer referral; however, it should not be consideredcomprehensivenorutilizedtolimitaccesstogeneticsprofessionals. Whiletheprinciplesoutlinedforgeneticsreferralforthe specific tumors andsyndromes listedremain valid, inmany casesthe indications forreferral have expanded.The field ofcancer genetics israpidlyevolving,includingfrequentdiscovery ofadditionalgenesandnewclinicalpresentations

2019 American College of Medical Genetics and Genomics

7. Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis

Programmed Death-1 or Programmed Death Ligand-1 Blockade in Patients with Platinum-resistant Metastatic Urothelial Cancer: A Systematic Review and Meta-analysis Several anti-programmed death-1 (anti-PD-1) and anti-programmed death ligand-1 (anti-PD-L1) antibodies have been approved by regulatory authorities for treatment of platinum-resistant metastatic urothelial cancer (mUC). The impact of these therapies on survival, and comparability of PD-1 versus PD-L1 blockade are unknown.To determine (...) versus PD-L1 blockade in patients with mUC yields comparable survival outcomes.In this study, we found that outcomes for patients with metastatic bladder cancer treated with programmed death-1 and programmed death ligand-1 inhibitors, who received prior platinum-based chemotherapy, were similar.Copyright © 2019 European Association of Urology. Published by Elsevier B.V. All rights reserved.

2019 EvidenceUpdates

8. Multicentre randomized clinical trial of colonic J pouch or straight stapled colorectal reconstruction after low anterior resection for rectal cancer

Multicentre randomized clinical trial of colonic J pouch or straight stapled colorectal reconstruction after low anterior resection for rectal cancer Colonic J pouch reconstruction has been found to be associated with a lower incidence of anastomotic leakage than straight anastomosis. However, studies on this topic are underpowered and retrospective. This randomized trial evaluated whether the incidence of anastomotic leakage was reduced after colonic J pouch reconstruction compared

2019 EvidenceUpdates

9. Treatment of superficial œsophageal cancer by endoscopic submucosal dissection (ESD)

Treatment of superficial œsophageal cancer by endoscopic submucosal dissection (ESD) Treatment of superficial œsophageal cancer by endoscopic submucosal dissection (ESD) - INAHTA Brief

2019 Haute Autorite de sante

10. Treatment of superficial stomach cancer by endoscopic submucosal dissection (ESD)

Treatment of superficial stomach cancer by endoscopic submucosal dissection (ESD) Treatment of superficial stomach cancer by endoscopic submucosal dissection (ESD) - INAHTA Brief

2019 Haute Autorite de sante

11. Clinical utility of genomic signatures in early-stage breast cancer

Clinical utility of genomic signatures in early-stage breast cancer Clinical utility of genomic signatures in early-stage breast cancer - INAHTA Brief

2019 Haute Autorite de sante

12. Treatment of superficial colon cancer by endoscopic submucosal dissection

Treatment of superficial colon cancer by endoscopic submucosal dissection Treatment of superficial colon cancer by endoscopic submucosal dissection - INAHTA Brief

2019 Haute Autorite de sante

13. Clinical utility of genomic signatures in early-stage breast cancer

Clinical utility of genomic signatures in early-stage breast cancer INAHTA Brief Issue 2019 Title Clinical utility of genomic signatures in early-stage breast cancer Agency HAS, French National Authority for Health (Haute Autorité de santé) 5 avenue du Stade de France – F 93218 La Plaine Cedex, France Tel: +33 (0)1 55 93 70 00, contact.seap@has-santé.fr, www.has-sante.fr Reference ISBN number 978-2-11-152376-0, link to full report https://www.has-sante.fr/portail/jcms/c_2748998/fr/utilite (...) - clinique-des-signatures-genomiques-dans-le-cancer-du-sein-de-stade-precoce-rapport-d-evaluation?xtmc=&xtcr=1 Aim Evaluate the clinical utility of four genomic signatures (GS) 1 , currently and temporarily funded on a conditional basis as part of a specific funding program for research and innovation (known in France as RIHN). The aim of the evaluation is to assess funding eligibility for the traditional reimbursement schemes offered by the National Health Insurance Fund. The four GS are decision-making

2019 Haute Autorite de sante

14. Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer Update

Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer Update Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update | Journal of Clinical Oncology Search in: Menu Article Tools ASCO SPECIAL ARTICLE Article Tools OPTIONS & TOOLS COMPANION ARTICLES No companion articles ARTICLE CITATION DOI: 10.1200/JCO.19.01461 Journal of Clinical Oncology - published online before print August 5, 2019 PMID: Venous Thromboembolism (...) Prophylaxis and Treatment in Patients With Cancer: ASCO Clinical Practice Guideline Update , MB ChB 1 x Nigel S. Key ; , MD 2 x Alok A. Khorana ; , MD 3 x Nicole M. Kuderer ; , ScD 4 x Kari Bohlke ; , MD, MSc 5 x Agnes Y.Y. Lee ; , MD, PhD 6 x Juan I. Arcelus ; , MD, MS 7 x Sandra L. Wong ; , DO 8 x Edward P. Balaban ; , MD, MS 9 x Christopher R. Flowers ; , MD 10 x Charles W. Francis ; 11 x Leigh E. Gates ; , MBBS, PhD 12 x Ajay K. Kakkar ; , MD, MSc 13 x Mark N. Levine ; , MD 14 x Howard A. Liebman

2019 American Society of Clinical Oncology Guidelines

15. Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging

Strategies to Identify Women at High Risk of Advanced Breast Cancer During Routine Screening for Discussion of Supplemental Imaging Federal legislation proposes requiring that screening mammography reports to practitioners and women incorporate breast density information and that women with dense breasts discuss supplemental imaging with their practitioner given their increased risk of interval breast cancer. Instead of discussing supplemental imaging with all women with dense breasts, it may (...) be more efficient to identify women at high risk of advanced breast cancer who may benefit most from supplemental imaging.To identify women at high risk of advanced breast cancer to target woman-practitioner discussions about the need for supplemental imaging.This prospective cohort study assessed 638 856 women aged 40 to 74 years who had 1 693 163 screening digital mammograms taken at Breast Cancer Surveillance Consortium (BCSC) imaging facilities from January 3, 2005, to December 31, 2014. Data

2019 EvidenceUpdates

16. Alpelisib (Piqray) - Breast cancer

Alpelisib (Piqray) - Breast cancer Drug Approval Package: Piqray U.S. Department of Health and Human Services Search FDA Submit search Drug Approval Package: Piqray Company: Novartis Pharmaceuticals Corporation Application Number: 212526 Approval Date: 05/24/2019 Persons with disabilities having problems accessing the PDF files below may call (301) 796-3634 for assistance. FDA Approval Letter and Labeling (PDF) (PDF) FDA Application Review Files (PDF) (PDF) (PDF) (PDF) (PDF) (PDF) Date created

2019 FDA - Drug Approval Package

17. Seaweed Consumption and Its Effect on Breast Cancer

Seaweed Consumption and Its Effect on Breast Cancer "Seaweed Consumption and Its Effect on Breast Cancer" by Alyssa MouaLee and Thanita Pradhanang < > > > > > Title Author Date of Graduation Summer 8-10-2019 Degree Type Capstone Project Degree Name Master of Science in Physician Assistant Studies Rights . Abstract Background: Breast cancer remains the most common cancer in women worldwide. Interestingly, breast cancer incidence varies dramatically among countries. Japan, in particular, has (...) relatively low breast cancer (BC) rates when compared to those in Western countries. Daily consumption of seaweed has been proposed as one of the factors in explaining the difference in incidence rates of BC. The high concentrations of polysaccharides in seaweed have been reported in many studies to have anti-cancer effects as well as chemoprotective effects. The aim for this review is to look at the potential benefits of seaweed consumption and its effect on breast cancer. Methods: Exhaustive search

2019 Pacific University EBM Capstone Project

18. Palbociclib (Ibrance) - hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer

Palbociclib (Ibrance) - hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer 1 Published 8 July 2019 1 SMC2149 palbociclib 75mg, 100mg, and 125mg hard capsules (Ibrance®) Pfizer Limited 7 June 2019 The Scottish Medicines Consortium (SMC) has completed its assessment of the above product and advises NHS Boards and Area Drug and Therapeutic Committees (ADTCs) on its use in NHSScotland. The advice is summarised (...) as follows: ADVICE: following a full submission considered under the end of life and orphan equivalent assessment process. palbociclib (Ibrance ® ) is accepted for use within NHSScotland. Indication under review: for the treatment of hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative locally advanced or metastatic breast cancer: - in combination with an aromatase inhibitor; - in combination with fulvestrant in women who have received prior endocrine therapy. In pre

2019 Scottish Medicines Consortium

19. Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis

Association Between Adjuvant Chemotherapy Duration and Survival Among Patients With Stage II and III Colon Cancer: A Systematic Review and Meta-analysis The results from the recent International Duration Evaluation of Adjuvant Therapy (IDEA) collaboration have led some clinicians to adopt shorter durations of adjuvant chemotherapy for patients with stage III colon cancer. The extent to which these findings are supported by other data is unknown.To conduct a systematic review and meta-analysis (...) of randomized and observational studies investigating the association between the duration of adjuvant chemotherapy and survival among individuals diagnosed as having stage II and III colon cancer (PROSPERO protocol CRD42018108711]).Abstracts published in English between 2003 and 2018 within the MEDLINE, Embase, CENTRAL, and CINAHL databases were reviewed by 2 authors. Also searched were conference proceedings and the indexes of high-impact oncology journals.Studies were excluded if they did not present

Full Text available with Trip Pro

2019 EvidenceUpdates

20. Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial

Trebananib or placebo plus carboplatin and paclitaxel as first-line treatment for advanced ovarian cancer (TRINOVA-3/ENGOT-ov2/GOG-3001): a randomised, double-blind, phase 3 trial Angiopoietin 1 and 2 regulate angiogenesis and vascular remodelling by interacting with the tyrosine kinase receptor Tie2, and inhibition of angiogenesis has shown promise in the treatment of ovarian cancer. We aimed to assess whether trebananib, a peptibody that inhibits binding of angiopoietin 1 and 2 to Tie2 (...) , improved progression-free survival when added to carboplatin and paclitaxel as first-line therapy in advanced epithelial ovarian, primary fallopian tube, or peritoneal cancer in a phase 3 clinical trial.TRINOVA-3, a multicentre, multinational, phase 3, double-blind study, was done at 206 investigational sites (hospitals and cancer centres) in 14 countries. Eligible patients were aged 18 years or older with biopsy-confirmed International Federation of Gynecology and Obstetrics (FIGO) stage III to IV

2019 EvidenceUpdates